Honors Theses
Date of Award
Spring 5-8-2025
Document Type
Undergraduate Thesis
Department
School of Pharmacy
First Advisor
Erin Holmes
Second Advisor
Joe Dikun
Third Advisor
Marie Barnard
Relational Format
Dissertation/Thesis
Abstract
Glucagon-like peptide-1 (GLP-1) receptor agonists are a novel class of medications used primarily for the treatment of type 2 diabetes, as well as for chronic weight management. The first GLP-1 medication, exenatide, was FDA-approved in April of 2005 for glycemic control, however, it was not until December of 2014 when liraglutide became the first GLP-1 FDA-approved for weight loss. There are now eight FDA-approved GLP-1s, only two of which are approved for weight loss. GLP-1 use has become increasingly popular in recent years, even extending to the college-aged population. The purpose of this study is to examine the trends in GLP-1 use, as well as the opinions surrounding the use of GLP-1s in college students.
Interviews were conducted with three local Oxford pharmacists, as well as two students attending The University of Mississippi who have been prescribed GLP-1s. The data collected was used to gain a more holistic view of pharmacist and patient views on the increase in GLP-1 medication use among college students, and to provide a basis for future research and analyses of GLP-1s.
Recommended Citation
Bradley, Maci, "A Local Assessment of GLP-1 Use for Weight Loss: An Interview Study" (2025). Honors Theses. 3321.
https://egrove.olemiss.edu/hon_thesis/3321
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Included in
Mental and Social Health Commons, Pharmacy and Pharmaceutical Sciences Commons, Public Health Commons
